Heron Therapeutics, Inc. HRTX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in HERON THERAPEUTICS, INC. /DE/'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.
Growth
Revenue compounded at +11.8% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Return on equity has no reading this year — return on capital employed, just below, still does: -2%.
The 17-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | −0.0 |
| Net income $B | −0.0 | −0.0 | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.12 | −0.09 | −0.80 | −1.67 | −2.24 | −2.50 | −2.50 | −2.44 | −3.65 | −4.56 | −2.95 | −2.87 | −3.42 | −1.91 | −1.96 | −0.19 | −0.31 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | — | — | — | −399.4 | −140.5 | −71.0 | −52.9 | −71.4 | — | — | −107.7 | −115.7 | −91.6 | −69.1 | −138.4 | −181.1 | −147.6 |
| Shares out B | 0.19 | 0.15 | 0.15 | 0.12 | 0.10 | 0.09 | 0.09 | 0.08 | 0.06 | 0.00 | 0.04 | 0.03 | 0.02 | 0.30 | 0.20 | 0.04 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 17 of the 17 fiscal years we could check. Nine checks were skipped: revenue is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.